Kypros D Tablet ER is a combination medication containing Tamsulosin 0.4 mg and Dutasteride 0.5 mg, formulated as an extended-release tablet for the management of benign prostatic hyperplasia (BPH). Tamsulosin is an alpha-1 adrenergic receptor antagonist that selectively relaxes smooth muscle in the prostate and bladder neck, improving urinary flow and reducing symptoms associated with BPH. Dutasteride is a 5-alpha-reductase inhibitor that decreases the conversion of testosterone to dihydrotestosterone (DHT), leading to a reduction in prostate volume over time. The combined action of these agents addresses both the dynamic and static components of BPH, providing symptomatic relief and reducing the risk of disease progression. Kypros D Tablet ER is indicated for men with moderate to severe BPH who may benefit from dual therapy to improve urinary symptoms and decrease the need for surgical intervention. The extended-release formulation ensures a steady plasma concentration, enhancing patient compliance by allowing once-daily dosing. Common adverse effects may include dizziness, headache, ejaculation disorders, and potential hypersensitivity reactions. Use of Kypros D should be under medical supervision, with periodic monitoring of prostate-specific antigen (PSA) levels recommended to detect any changes suggestive of prostate malignancy.